Related Experiment Video
Updated: Mar 14, 2026

09:39
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
16.1K
Myotonic Dystrophy and Huntington's Disease Care: "We Like to Think We're Making a Difference"
Kori A LaDonna1, Christopher J Watling1, Susan L Ray2
11Centre for Education Research & Innovation,Schulich School of Medicine & Dentistry,Western University,London,Ontario,Canada.
Summary
Health care providers adapt care for myotonic dystrophy (DM1) and Huntington
Area of Science:
- Neurology
- Patient Care
- Healthcare Management
Background:
- Myotonic dystrophy (DM1) and Huntington's disease (HD) are progressive, life-limiting neurological conditions.
- Cognitive and behavioral impairments in patients can challenge patient-centered care.
- No prior research explored healthcare providers' (HCPs') perspectives on patient-centered care for DM1/HD patients.
Purpose of the Study:
- To explore healthcare providers' perspectives on delivering patient-centered care to individuals with myotonic dystrophy (DM1) and Huntington's disease (HD).
Main Methods:
- Constructivist grounded theory approach.
- Semistructured interviews with eleven HCPs treating DM1 or HD patients.
- Iterative data collection and analysis using three stages of coding.
Main Results:
- HCPs described an evolving care approach based on disease stage and caregiver involvement.
- Key goals included providing hope through medical management, crisis prevention, support, and advocacy.
- HCPs perceived patients benefited from proactive clinical care despite the absence of curative treatments.
Conclusions:
- Care for DM1/HD patients involves balancing care provision challenges and rewards.
- HCPs must balance symptom management with quality of life concerns for patients and caregivers.
- The study raises questions about the feasibility of patient-centered care with cognitive decline and the evolution of chronic neurological care.
Keywords:
Huntington’s diseasemyotonic dystrophyneurological practiceneurology - clinicalneurology - educationMore Related Videos
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
574
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
574
Satellite Stem Cells and Muscular Dystrophy
2.5K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
611
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
611
Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Cardiomyopathy II: Dilated Cardiomyopathy
705
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
705

